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The influence of a home-based exercise
intervention on human health indices in
individuals with chronic spinal cord injury
(HOMEX-SCI): study protocol for a
randomised controlled trial
Tom E. Nightingale, Jean-Philippe Walhin, James E. Turner, Dylan Thompson and James L. J. Bilzon*
Abstract
Background: Spinal cord injury (SCI) creates a complex pathology that can lead to an increase in sedentary
behaviours and deleterious changes in body composition. Consequently, individuals with SCI are at increased risk of
developing cardiovascular disease and type-2 diabetes mellitus. While the role of physical activity on the reduction
of chronic disease risk is well documented in non-disabled individuals the evidence is less conclusive for persons
with SCI. The aim of this methodological paper is to outline the design of a study that will assess the role of a
home-based exercise intervention on biomarkers of metabolic and cardiovascular health in persons with SCI: the
HOMEX-SCI study.
Methods/design: Eligible participants will be inactive (physical activity level ≤1.60) individuals, with a chronic
(more than 1 year) spinal cord lesion between the second thoracic and the fifth lumbar vertebrae, and aged
between 18 and 65 years. Following baseline laboratory testing and lifestyle monitoring, participants will be
randomly allocated to a control (CON) group or a 6-week home-based exercise intervention (INT) group. The INT
consists of 45 minutes of moderate-intensity (60–65 % peak oxygen uptake) arm-crank exercise four times per
week. Participants assigned to the CON group will be asked to maintain their normal lifestyle. The main outcomes
of this study (biomarkers of metabolic and cardiovascular health) are obtained from venous blood samples,
collected in the fasted and postprandial state. Eight other measurement categories will be assessed: (1) body
composition, (2) physical activity, (3) energy intake, (4) measures of health and wellbeing, (5) resting metabolic rate,
heart rate and blood pressure, (6) aerobic capacity, (7) immune function, and (8) adipose tissue gene expression.
Discussion: This study will explore the feasibility of home-based moderate-intensity exercise and ascertain its
impact on metabolic and cardiovascular health in comparison to a lifestyle maintenance CON group. Findings from
this study may help to inform new evidence-based physical activity guidelines and also help to elucidate the
physiological mechanisms whereby exercise might exert beneficial effects in persons with chronic SCI. The results
will also act as a scientific platform for further intervention studies in other diverse and at-risk populations.
Trial registration: International Standard Randomised Controlled Trial Number: ISRCTN57096451. Registered on
11 July 2014.
Keywords: Aerobic capacity, Metabolic health, Paraplegia, Spinal cord injury, Physical activity, Immune function,
Inflammation, Gene expression, Exercise intervention
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Background
A spinal cord injury (SCI) is a significant life-changing
event which has wide-ranging implications for multiple
physiological systems. There are no reliable estimates of
the global prevalence of SCI, perhaps reflecting the need
for improvements in international medical standards
and guidelines for reporting SCI. Over the past 60 years
there has been a worldwide improvement in the acute
survival of patients with traumatic SCI through the
possibility of rapid transportation to a specialised unit,
medical treatment advancements and improved rehabili-
tation [1]. As a consequence there has been a shift in
focus from acute life support medicine, to addressing
other secondary health complications and comorbidities
associated with ageing with paralysis [2, 3]. Conse-
quently the long-term demands on medical and support
resources are high. A recent systematic review examin-
ing survival worldwide after SCI concluded that overall
mortality in SCI is up to three times higher than in the
general population [4]. Evidence now suggests that car-
diovascular disease (CVD) is the leading cause of mor-
tality in individuals with chronic SCI [5]. Besides CVD,
epidemiological studies have also revealed the incidence
of type-2 diabetes mellitus (T2DM) to be high in indi-
viduals with SCI [6–8]. Indeed, it has been suggested
that adults with SCI are four times more likely to de-
velop T2DM than non-disabled controls [9].
The contribution of regular physical activity (PA) to
reduce the risk of these chronic diseases is well docu-
mented and broadly accepted in the non-disabled popu-
lation [10, 11]. In individuals with SCI, involvement in
sports and recreation is often restricted by the loss of
voluntary motor control, as well as autonomic dysfunc-
tion and early onset of skeletal muscle fatigue [12–14].
There are also numerous psychosocial and environmen-
tal barriers: reduced self-esteem, lack of accessible facil-
ities, unaffordable equipment, fear of injury and/or
excessive parental or care protection, which have all
been cited as barriers to engagement in PA [15–18]. It is
likely that the adoption of a more sedentary lifestyle
[19–21], in conjunction with reduced physical function
[22], and adverse changes in body composition [23, 24]
(e.g. lower limb skeletal muscle atrophy [25, 26]) after
SCI, contribute to the increased morbidity and mortality
associated with this population.
There is convincing evidence to suggest that compo-
nent risks for the development of metabolic syndrome
occur at a heightened frequency in individuals with SCI;
specifically, increased central obesity [27–29], impaired
fasting glucose/T2DM [30, 31] and dyslipidaemia [32].
The accumulation of excess adiposity is thought to be
associated with a sustained positive energy balance sec-
ondary to reductions in resting metabolic rate and phys-
ical activity energy expenditure. This is associated with
local and systemic inflammation, with studies demon-
strating a two to threefold increase in the levels of cir-
culating inflammatory markers in persons with SCI
compared to non-disabled persons [33–35]. Although el-
evated chronic inflammation is not formally included
among evidence-based metabolic syndrome compo-
nents, its role in the development of atherosclerosis has
been extensively characterised [36–38]. Although it was
previously thought that adipose tissue was simply a store
for energy, this dynamic tissue is now recognised as an
endocrine organ [39–41]. Adipose tissue secretes a num-
ber of hormones, collectively termed ‘adipokines’, which
play a key role in regulating glucose metabolism and in-
sulin sensitivity, as well as governing aspects of immune
function and a variety of other physiological processes.
Indeed, the expression of many adipokines is markedly
dysregulated with excess adiposity [42] and in individ-
uals with SCI [43, 44]. Although a causal link has not
been robustly confirmed, several aspects of immune
function are also impaired in sedentary, overweight and
obese individuals [45–49] and it is possible that these
findings may generalise to individuals with SCI [50].
The impact of physical activity on health in persons with
spinal cord injury
Various biological mechanisms, integral in the mainten-
ance of metabolic control, are influenced by physical in-
activity and have been implicated in the progression of
certain chronic diseases [51]. To date, cross-sectional
evidence has been used to inform PA guidelines for indi-
viduals with SCI. These disability-specific guidelines
[52], developed as part of the Study of Health and Activ-
ity in People with Spinal Cord Injury (SHAPE SCI) [53,
54], propose that at least 20 minutes of moderate- to
vigorous-intensity aerobic activity should be undertaken
twice a week by people with SCI. These guidelines were
developed through a systematic and critical appraisal of
research to date, which was then deliberated by a multi-
disciplinary expert panel to assess the quality of the evi-
dence. The comprehensive systematic review to compile
this evidence indicated that most studies informing these
guidelines were of poor quality and focused solely on
physical capacity and muscular strength [54]. Therefore,
there is a lack of empirical evidence regarding the most
appropriate dose of exercise or physical activity parame-
ters (e.g. frequency, duration) for improving metabolic
health in this population.
The current literature on PA research for individuals
with SCI has recently been systematically classified [55].
Most studies between 2000 and 2012 have been cate-
gorised as either: phase 1 (linking PA and health out-
comes); phase 2 (validating or developing PA monitors) or;
phase 3 (identifying factors influencing behaviour or exam-
ining theories of behaviour change). Such categorisation
Nightingale et al. Trials  (2016) 17:284 Page 2 of 12
implies that this field is in the early stages of development
and research should now focus on phase 4 (evaluating in-
terventions) and phase 5 (disseminating health promotion
policies and translating research into practice). Due to the
inconsistent findings across studies, concluded via a sys-
tematic review requested by the Consortium for Spinal
Cord Medicine [56], it would appear that current evidence
is insufficient to determine whether exercise improves
carbohydrate and lipid metabolism disorders among
adults with SCI. However, previous studies have demon-
strated that arm-crank exercise improves lipid profiles
[57], inflammatory biomarkers [58] and fasting insulin
concentrations [59] with interventions ranging from 12 to
16 weeks in duration. It is possible that inconsistencies in
the current literature may be caused by considerable het-
erogeneity in study participants, the type of exercise
programme and/or the outcome measures examined.
Here we describe the study design for a randomised con-
trolled trial (RCT) with a homogeneous cohort, examining
a variety of outcome measures not simply confined to
physical capacity, that will contribute towards our un-
derstanding of how a home-based upper body exercise
intervention might impact metabolic, cardiovascular
and immunological health in individuals with SCI: the
HOMEX-SCI study.
Objectives
The primary objective of the HOMEX-SCI study is to
assess the impact of a 6-week home-based moderate-
intensity arm-crank exercise intervention on markers of
metabolic and cardiovascular health in inactive individuals
with chronic SCI. Little is known about the impact of a
moderate- to vigorous-intensity exercise intervention on
messenger ribonucleic acid (mRNA) expression of adipose
tissue, which is surprising considering that it is a major
site for energy storage. To our knowledge, adipose tissue
biology has never been studied in a cohort of individuals
with SCI. Thus, a secondary objective is to investigate at
baseline, and following intervention, the expression of
genes within adipose tissue that are associated with a var-
iety of biological processes such as energy homeostasis,
glucose metabolism, lipid metabolism and inflammatory
responses. Other objectives include: characterising aspects
of adaptive immune function pre and post intervention,
quantifying changes in body composition, aerobic cap-
acity, dietary and physical activity behaviours and various
constructs of health and wellbeing. The exercise interven-
tion group’s responses, for all outcome measures over
6 weeks, will be compared to a control group.
Methods
Study design
This study is a pre-post, parallel-group design, with par-
ticipants randomly assigned to a 6-week home-based ex-
ercise intervention (INT) or a control period (CON).
The planned experimental design is summarised below
(Fig. 1), consistent with current Consolidated Standards
of Reporting Trials (CONSORT) guidelines [60]. The
South West (Exeter) National Research Ethics Service
Committee has approved this study protocol (REC refer-
ence number 14/SW/0106) and the trial has been regis-
tered as a current controlled trial (ISRCTN57096451).
Upon initial contact (by email or telephone), the study
will be described briefly and those interested in enrolling
will be asked to read a detailed participant information
sheet and complete a health screen questionnaire. Inter-
ested individuals will be screened via a telephone con-
versation 48 hours after their initial contact to ascertain
Fig. 1 Study flow diagram (Abbreviations: CON control group, INT exercise intervention group, PA physical activity, PAL physical activity level,
T2DM type-2 diabetes mellitus, V̇O2 peak peak oxygen uptake)
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eligibility. A focus will be placed on establishing a good
rapport at this initial contact and also as individuals pro-
gress through the enrolment process. Written consent
will be obtained during the initial laboratory visit and
participants will be informed that they can withdraw
from the study at any time without consequence.
Baseline laboratory testing will be performed in the
Centre for DisAbility Sport and Health (DASH) at the
University of Bath approximately 2 weeks before the
INT/CON period commences. During this 2-week in-
terim period participants will be instructed not to alter
their normal activity patterns or dietary behaviours. This
period permits a 7-day estimation of free-living habitual
energy balance, whereby PA is monitored and partici-
pants are asked to maintain a detailed weighed record of
food intake. The additional time accounts for partici-
pants returning the activity monitors, and downloading
and subsequent analysis of data to ascertain participant
eligibility. A member of the research team will also travel
to each participant’s home to deliver a portable arm-
crank ergometer and supervise the first exercise session.
Importantly, the interim period also allows exactly 8 weeks
between baseline and follow-up testing, which ensures
that eumenorrheic female participants will be within the
follicular phase of their menstrual cycle (3–10 days after
the onset of menses) during both laboratory visits. Con-
trolling for menstrual cycle stage is important as hormone
fluctuations can influence insulin sensitivity [61].
Recruitment and randomisation
It has been reported that recruitment for a RCT, espe-
cially in the absence of direct access to a clinical popu-
lation, requires considerably more resources and time
than initially anticipated in order to achieve adequate
enrolment [62]. In a systematic review, Ross et al., [63]
described patient barriers to recruitment for RCTs.
These included: (1) additional demands of the trial in-
creasing participant burden and (2) patient preferences
for or against a particular treatment. Barriers to re-
search participation are perhaps even more exaggerated
for people with disabilities due to complex health prob-
lems [64], lack of transportation [65], cognitive impair-
ments and financial stress [66]. With this in mind, we
plan to deliver the intervention by setting up arm-crank
ergometers in participants’ own homes, thereby mini-
mising any potential accessibility/transport barriers to
participants becoming more active. Transportation
needs are a major participation barrier for individuals
with disabilities, and so travel expenses to the Univer-
sity of Bath for laboratory testing will be reimbursed.
Recruitment material will be promoted by nationwide
charities and circulated on Internet forums and social
networking sites. Previous Centre for DisAbility Sport
and Health research participants who met the inclusion
criteria of the trial have been notified directly about the
study via email.
After baseline laboratory testing and habitual free-
living monitoring, the first nine participants will be ran-
domly allocated to the experimental group (INT) or the
CON group using a block randomisation plan (fixed
block size of nine; allocation ratio of 2:1; no stratifica-
tion). Randomisation will be performed by an independ-
ent researcher using a concealed list generated with a
web-based platform (www.randomization.com). Within
a highly heterogeneous population such as individuals
with SCI, we decided to use minimisation [67] to ensure
balance between the two groups for baseline characteris-
tics (age, body mass, level of spinal cord lesion and phys-
ical activity level). Subsequent participants who enrol on
the trial will, therefore, be allocated to either the INT
group or the CON group in order to balance the groups
in these variables of interest. We opted for an unequal
allocation ratio as it has been supported as an alternative
approach for ‘confirmatory trials’ [68, 69], primarily to
increase the amount of data on the INT, where individ-
ual responses are likely more variable. We presume lim-
ited variability in the CON group, as participants will
continue to live their normal lifestyle. Any small loss of
precision with the use of unequal allocation has been ap-
propriately accounted for in the sample size calculation.
While participants may have a strong preference to re-
ceive the INT and not be in the CON group, we will try
to overcome this by offering a waiting-list control. Par-
ticipants in the CON group will, therefore, be offered
the opportunity to participate in the INT once they have
completed the CON period.
Participants and eligibility criteria
The participants will be inactive individuals (physical ac-
tivity level; PAL ≤1.60), with a chronic (more than 1 year)
spinal cord lesion between the second thoracic and the
fifth lumbar vertebrae, who are aged between 18 and
65 years. Volunteers with neurologically incomplete in-
juries will be considered eligible if they are wheelchair
users for more than 75 % of their waking day. Partici-
pants will only be included if they have been weight
stable (±3 kg) for at least 6 months and have no plans to
change their diet or exercise behaviours. Individuals self-
reporting active medical issues including pressure sores,
urinary tract infections, cardiac disorders, cardiovascular
contra-indications for testing [70] or musculoskeletal
complaints of the upper extremities will be excluded.
Participants on T2DM medication will also be excluded.
Habitual PAL will be estimated over a representative
7-day period following the baseline laboratory visit using
a wearable PA-monitoring device (Actiheart™, Cambridge
Neurotechnology Ltd., Papworth, UK), which integrates
accelerometer and heart rate signals. This device has
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previously been validated for use in this population [71].
Participants will wear this monitor continuously (24 hours
a day) and will be instructed only to remove it when
showering or bathing. Individuals with a PAL >1.60 will be
precluded from progressing to the group allocation stage.
Main trial day protocol
The same experimental procedures will be completed on
both baseline and follow-up trial days. Participants will
arrive at the Centre for DisAbility Sport and Health
laboratory at 08.30 ± 1 h, following an overnight fast (at
least 10 h). Twenty-four hours prior to each main
laboratory trial day, participants will abstain from
strenuous exercise, caffeine (tea/coffee) and alcohol. The
final exercise bout prescribed in the INT group will be
more than 36 h prior to follow-up testing in order to re-
duce the acute effects from the previous bout of exer-
cise. Participants will also be asked to consume 1 pint of
water on the morning of testing to ensure adequate hy-
dration. See Fig. 2 for the schematic overview of the
main trial day timeline.
Body composition analysis
After being asked to void, body mass will be measured,
with participants wearing light clothing, using platform
wheelchair scales (Detecto® BRW1000, Webb City, MO,
USA). The wheelchair, along with participants’ shoes will
be weighed separately and subtracted from the total
mass of the participant to derive an accurate body mass
as recommended [72]. For body composition analysis,
participants will transfer onto a Dual-energy X-ray Ab-
sorptiometry (DEXA) scanning table (Discovery, Hologic,
Bedford, UK). Supine height will be measured in centi-
metres along the left hand side of the body using a
non-elastic tape measure (Lufkin, Sparks, MD, US).
Participants will be positioned centrally on the scan-
ning table with their feet spaced evenly either side of
the mid-point of the body, with their arms placed mid-
prone with an equal gap to the trunk on both sides. For
participants who experience leg spasms, their knees
will be flexed at a 45°-angle and supported by a pillow.
Participants will be instructed to remain as still as pos-
sible. All scans will be conducted following a daily QC
scan of a Spine Phantom as per the manufacturer’s
instructions.
Resting metabolic rate measurement
Resting metabolic rate (RMR) will be estimated by indir-
ect calorimetry from expired air samples collected into
200-L Douglas Bags (Hans Rudolph, Kansas City, MO,
USA) via falconia tubing (Baxter, Woodhouse and Taylor
Ltd., Macclesfield, UK) with concurrent measurement of
inspired air composition; a reliance of standard atmos-
pheric concentrations has recently been discouraged
[73]. The process of indirect calorimetry has previously
been described in detail [74]. Expired concentrations of
oxygen (O2) and carbon dioxide (CO2) will be measured,
from a known volume of each sample using paramag-
netic and infrared analysers, respectively (MiniMP 5200,
Servomex Ltd., Sussex, UK). Four 5-min Douglas Bag
samples will be collected for RMR in accordance with
best practice guidelines [75]. Measurements will be con-
ducted following a 20-min rest and ambient laboratory
temperature will be maintained between 20 and 25 °C.
RMR will be taken as the average of two or more
Douglas Bag samples that are within 100 kcal day−1 of
each other. Participants will also wear a Polar T31 heart
rate monitor (Polar Electro Inc., Lake Success, NY, USA)
during RMR measurement; resting heart rate values will
be averaged over the 20-min collection period.
Fig. 2 Schematic overview of main trial day timeline, with 08.00 arrival time of the participant as an example (Abbreviations: RMR resting
metabolic rate)
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Blood sampling
After a 15-min supine rest, a cannula (BD Venflon Pro,
BD, Helsingborg, Sweden) will be inserted into an ante-
cubital vein, and a 45-ml fasting sample drawn. From
this sample, 25 ml of whole blood will be collected into
sodium heparin tubes and peripheral blood mononuclear
cells (PBMCs) will be isolated using density gradient
centrifugation using standard methods. Cells in freezing
medium (70 % Roswell Park Memorial Institute (RPMI)
media, 20 % fetal bovine serum (FBS), 10 % dimethyl-
sulphoxide (DMSO)) will be frozen at −1 °C/min using a
Nalgene ‘Mr Frosty’ container. Samples will be stored at
−80 °C and assayed for immunological measurements
within 12 months.
The remaining blood from the baseline sample (and
subsequent blood samples during the oral glucose toler-
ance test; see oral glucose tolerance test section below)
will divided into separate tubes for obtaining serum and
plasma. For serum, whole blood will be placed into a
serum separation tube and left to stand at room
temperature for 15 min before centrifugation. For
plasma, whole blood will be placed into tubes coated
with ethylenediaminetetraacetic acid (EDTA) and centri-
fuged immediately. Samples will be centrifuged (Heraeus
Biofuge Primo R, Kendro Laboratory Products Plc., Tyne
and Wear, UK) at 5000 rpm for 10 min at 4 °C, with
serum/plasma subsequently dispensed into 0.5-ml ali-
quots and immediately cooled on dry ice and then
stored at −80 °C. A small aliquot of EDTA blood will be
used to obtain the full leucocyte differential and other
haematological variables (SF-300, Sysmex Ltd., Milton
Keynes, UK).
Adipose tissue biopsy
An adipose tissue sample will be collected from the area
around the waist, approximately 5 cm lateral to the um-
bilicus, using a well-established ‘needle aspiration’ tech-
nique [76]. The area will be thoroughly disinfected with
Videne, before injection of anaesthetic (approximately
5 ml lignocaine hydrochloride 1 %) into a small area.
Five minutes later, a needle will be inserted in the sub-
cutaneous fat tissue around the waist in order to collect
approximately 1–2 g of fat tissue. Swabs and pressure
will be applied to the area once the sample has been
collected. A dressing will then be applied to the area.
The sample will be cleaned with isotonic saline and any
clots will be manually removed. After the sample has
been weighed, it will be homogenized in 5 ml of Trizol
(Invitrogen, Paisley, UK) and stored at −80 °C.
Oral glucose tolerance test (OGTT)
After the baseline blood sample and adipose tissue biopsy,
the participant will consume 113 ml of Polycal (Polycal,
Nutricia Advanced Medical Nutrition, Trowbridge, UK)
and 87 ml of water, equivalent to 75 g of anhydrous glu-
cose, within 5 minutes. Further 5-ml blood samples will
be drawn at 15-min intervals for the next 2 hours. The
intravenous cannula is to be kept patent through periodic
flushing with 0.9 % NaCl (B. Braun, Sheffield, UK) infu-
sion, with the first 5 ml of each blood draw being dis-
carded. Blood pressure will also be measured during the
final 15 min of the OGTT using an automated blood pres-
sure monitor (Boso Medicus Prestige, Bosch + Sohn
GmbH, Jungingen, Germany). The short form-36 health
survey (SF-36), the EuroQol-5 dimensions, 5 levels ques-
tionnaire (EQ-5D-5 L), the Wheelchair User’s Shoulder
Pain Index (WUSPI), the Fatigue Severity Scale (FSS) and
the Exercise Self-efficacy Scale (ESES) will be administered
during the last 30 min of the OGTT.
Exercise testing pre and post intervention
Participants will undertake an incremental submaximal
arm-crank ergometry test using a portable desktop erg-
ometer (Monark compact rehab 871E, Dalarna, Sweden).
This test will comprise three 3-min stages, separated by
a 1-min rest period during which the resistance will be
increased. Participants will be instructed to maintain a
cadence of 75 rpm throughout. A variety of power out-
puts will be chosen that are sufficient to cover the rela-
tive exercise intensities (60–65 % of V̇O2 peak)
employed during training sessions in the INT group.
During the final minute of each stage, V̇O2 and heart
rate will be recorded to determine the relationships be-
tween V̇O2, exercise intensity (work rate) and heart rate.
This test will be performed on the same ergometer pro-
vided to each participant during the INT.
Peak oxygen uptake (V̇O2 peak) will be determined at
the end of each laboratory visit using a continuous, pro-
gressive intensity test on an electrically braked arm-
crank ergometer (Lode Angio, Groningen, Netherlands).
A cadence of 75 rpm will be encouraged throughout and
a starting intensity will be selected based on the partici-
pant’s training history. The resistance will be increased
by 14 W every 3 minutes until the point of volitional
exhaustion (approximately 9–12 min). Continuous gas ex-
change measurements will be collected using a TrueOne®
2400 computerized metabolic system (ParvoMedics, Salt
Lake City, UT, USA), calibrated according to manufac-
turer’s instructions prior to use.
Home-based exercise intervention
The exercise intervention will consist of moderate-
intensity (60–65 % V̇O2 peak) home-based exercise four
times per week on a portable desktop ergometer. The
intervention will progress by extending the duration of
each session by 5 minutes in the first week, from 30 to
45 min. The intensity will also be increased from ap-
proximately 60 % V̇O2 peak for the first 3 weeks to
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approximately 65 % V̇O2 peak for the final 3-week
period. Participants will be instructed to work at a cadence
of 75 rpm and will be able to schedule exercise sessions
around their own lifestyle (i.e. no restrictions with regards
to training on consecutive or non-consecutive days, week-
days or weekends). The first training session at each par-
ticipant’s home will be supervised by a member of the
research team to ensure that the arm-crank ergometer is
set up appropriately and that the correct duration and in-
tensity of exercise is adhered to. Subsequent home-based
exercise sessions will be performed under the supervision
of a carer or spouse as agreed on the informed consent
document. To attain the desired intensity in each session,
participants will wear a Polar T31 heart rate monitor
(Polar Electro Inc., Lake Success, NY, USA) and will be
instructed to adjust the resistance in order to achieve the
target heart rate. The target heart rate for each participant
will be calculated during baseline testing using V̇O2, work
rate and heart rate data collected during the incremental
submaximal arm ergometer test. If the V̇O2 and heart rate
relationship is influenced by a blunted cardiovascular re-
sponse to exercise in participants with higher-level injuries
(above T6) then a target work rate (W), derived from
the individual V̇O2 and work rate relationship, will be
prescribed instead. The intervention will be conducted
on the same portable desktop ergometer that submaxi-
mal exercise testing was performed on.
Each exercise session will be monitored via a GEN-
EActiv device (GENEActiv, Activinsights, Cambridge,
UK) worn on the wrist [77] to determine compliance.
Compliance records will be cross-checked with an activ-
ity diary where participants record the date, time, dur-
ation, difficulty and total revolutions of each exercise
session along with average heart rate during the last
10 minutes of exercise. Sampling at 30 Hz, the GEN-
EActiv is capable of recording PA for up to 3 weeks. At
the midway point a newly initialised and charged GEN-
EActiv device will be sent to the participant by standard
mail. During the final week of the intervention exercise
intensity compliance will be checked by heart rate re-
cordings on the Actiheart™ monitor. Adherence to the
intervention will be maintained with regular weekly tele-
phone calls and emails. No dietary constraints will be
imposed: participants in both groups will be free to con-
sume food and fluid ad libitum throughout.
Outcome measures
Body composition, resting metabolic rate and aerobic
capacity
To determine body composition, DEXA scans will be
analysed for total and regional (trunk, legs, arms) fat
mass, fat free mass, bone mineral content and fat per-
centage, following the guidelines described in the user
manual (Hologic, Bedford, UK). Fasting respiratory
exchange ratio (RER) will also be calculated during the
resting metabolic rate (kcal day−1) measurement. Aer-
obic capacity will be measured at the point of volitional
exhaustion during the incremental arm-crank test. A
number of criteria (participants must meet two of these)
will be applied to determine whether this endpoint is re-
flective of a valid V̇O2 peak value. These were: (1) a peak
RER value ≥1.1, (2) a peak heart rate of 95 % or more of
the age-predicted maximum (200 b min−1 minus chrono-
logical age) and an increase in V̇O2 ≤ 2 ml kg
−1 min−1 in
response to an increase workload [70]. Moreover, peak
workload (W) will be measured at volitional exhaustion.
Blood measurements
The metabolic and cardiovascular health, along with im-
mune function variables measured are shown in Table 1.
Besides the haematological profile which is measured
immediately during the main trial day, these variables
will be quantified during a batch analysis once the final
participant has completed the study. In order to simplify
data analysis and facilitate the interpretation of a com-
plex data set [78, 79], serial measurements of glucose
and insulin responses to the OGTT at baseline and
follow-up will be converted into simple summary statis-
tics [80], such as incremental area under the curve
(iAUC) [81] and insulin sensitivity index (ISIMatsuda) [82].
The Homeostasis Model Assessment (HOMA) calculator,
incorporating the updated HOMA-2 model [83], will be
used to derive fasting estimates of pancreatic β-cell func-
tion, insulin resistance and sensitivity.
Adipose tissue gene expression
The aqueous phase of stored adipose tissue samples will
be isolated and total ribonucleic acid (RNA) extracted
using the standard protocol supplied with RNeasy mini
columns (Qiagen, Crawley, UK). Approximately 2 μg of
total RNA will be reverse transcribed using a high-
capacity complementary deoxyribonucleic acid (cDNA)
reverse transcript kit (Applied Biosystem, Warrington,
UK). Pre-designed primers and probes will be obtained
from Applied Biosystems for each gene tested. Real-time
polymerase chain reaction (PCR) will be performed using
a StepOne™ (Applied Biosystems, Warrington, UK).
Measures of health and wellbeing
Quality of life and health status will be measured using
the SF-36 [84] and EQ-5D-5 L [85] self-report question-
naires, with certain questions adapted for wheelchair
propulsion instead of ambulation. Compared with four
other instruments used to measure health-related quality
of life in persons with SCI, Leduc and Lepage [86] re-
ported better validity of the SF-36 with regard to quanti-
fying the health status of participants. Original responses
will be transformed into recorded values (taking into
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account items which were negatively scored) and specific
questions will be averaged to return a value for general
health using the RAND 36-Item Health Survey 1.0 scor-
ing method. This value will range from 0 to 100, with
100 representing the best health possible. The EQ-5D-
5 L was developed by the EuroQol group and is applic-
able to a wide range of health conditions, including indi-
viduals with SCI [87].
Shoulder pain will be assessed using the WUSPI [88].
The performance-corrected WUSPI score (PC-WUSPI)
will be used as it accommodates participants who are un-
able to undertake certain functions (i.e. item 13: driving?).
This correction multiplies the average response for all
items by the number of questions attempted, with higher
values indicating a greater degree of perceived shoulder
pain. The FSS will be administered to measure the severity
of fatigue and its effects on certain behaviours. The FSS
was initially developed to be used in multiple sclerosis pa-
tients [89], but has also been shown to have acceptable
test-retest reliability and validity in 48 community living
individuals with SCI [90]. Self-efficacy will be assessed
using the SCI ESES [91], which was developed specifically
to cover issues associated with this unique population.
Physical activity energy expenditure
Daily physical activity energy expenditure will be esti-
mated before and during the final week of the INT/
CON period using an Actiheart™ monitor. Entering heart
rate and corresponding J min−1 kg−1 (derived from indir-
ect calorimetry) data measured throughout the trial day
(at rest and during a range of submaximal/maximal ex-
ercise intensities) into the manufacturer’s software
permits the individual calibration of this device. This
method has been previously validated for use in wheel-
chair users [71]. Raw acceleration signals (expressed as g
min−1) will also be recorded at baseline and follow-up
using a GENEActiv device worn on the wrist [77]. The
number of days required to assess habitual PA using
wearable devices has been discussed at length [92]. The
consensus was that monitoring for 3–4 days is required
to achieve 80 % reliability in activity counts. In our work we
decided to use an inclusion criteria of 4 days or more (pro-
viding one of these days was a weekend day). This criteria
also ensures that we capture more PA behavioural informa-
tion than the physical activity recall assessment for people
with a spinal cord injury (PARA-SCI: 3-day recall telephone
interview) which has been widely used to quantify free-
living PA in wheelchair users [53, 93]. A valid day will
require at least 80 % of data for that 24-h period. Data will
also be expressed as minutes spent in different intensities of
activities on the basis of metabolic equivalents (METs): sed-
entary <1.5 METs, light- 1.5–2.9 METs, moderate- 3.0–6.0
METs, and vigorous-intensity activity >6.0 METs.
Energy intake
Participants will be asked to keep a detailed record of
their food and fluid intake for a ‘typical’ 7 days. Previous
work has demonstrated variation between weekday and
weekend energy intake [94]; therefore, 7 days is a suit-
able period to allow accurate representation of habitual
energy intake. Each participant will receive a set of
weighing scales (PL11B Digital Scale, Smart Weigh,
Chestnut Ridge, NY, USA) to accurately weigh and rec-
ord foodstuffs, which negates any potential errors in the
Table 1 Metabolic health, cardiovascular disease risk and immune function variables
Haematological profile Analytical techniques
Red blood cell, white blood cell, neutrophil,
lymphocyte, monocyte and platelet counts,
haemoglobin concentrations, haematocrit
and haematic indices
Automated haematology system (SF-300, Sysmex Ltd., Milton Keynes, UK)
Biochemical variables Analytical techniques
Triglycerides, total cholesterol, NEFA,
HDL-C, LDL-C, glucose
Automated analyser (Randox RX Daytona, Randox Laboratories, Co. Antrim, UK), in accordance
with manufacturer’s instructions using commercially available immunoassays (Randox Laboratories,
Co. Antrim, UK).
Insulin ELISA (Mercodia AB, Uppsala, Sweden)
Adipokines Analytical techniques
Leptin and adiponectin ELISA (Quantikine HS, R&D Systems Inc., Abingdon, UK)
Inflammation Analytical techniques
IL-6 ELISA (Quantikine HS, R&D Systems Inc., Abingdon, UK)
CRP Automated analyser (Randox RX Daytona, Randox Laboratories, Co. Antrim, UK),
Immune function Analytical techniques
T cell anti-viral IFN-γ production Human IFN-γ ELISpotBASIC (Mabtech, Nacka Strand, Sweden)
CRP C-reactive protein, ELISA enzyme-linked immunosorbent assay, ELISpot enzyme-linked immunospot, HDL-C high-density lipoprotein cholesterol, IFN-γ interferon
gamma, IL-6 interleukin-6, LDL-C low-density lipoprotein cholesterol, NEFA non-esterified fatty acid
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estimation of food weight [95]. Martin et al., [96] have
shown that weighed food records are a more valid meas-
ure of energy intake than dietary recall methods. Diet re-
cords will subsequently be analysed using Nutritics
software (Nutritics Ltd., Dublin, Ireland), to estimate en-
ergy intake and macro-nutrient composition.
Statistical analysis
Changes in key outcome variables within and between
trials will be analysed with two-way (group [INT,
CON] × day [baseline, follow-up]) and three-way (group
[INT, CON] × day [baseline, follow-up × time]) mixed-
model analysis of variance (ANOVA). Where significant
interactions are observed, multiple t tests will determine
the location of variance both between treatments at each
time point and between time points within each treat-
ment relative to baseline. Both methods will be subjected
to a Holm-Bonferroni stepwise adjustment [97]. Standar-
dised effect sizes (Cohen’s d) will also be calculated for
all variables. Based upon the magnitude of correlation
between trials, thresholds of >0.2 (small), >0.5 (moder-
ate) and >0.8 (large) have been suggested [98]. This pro-
vides an interpretation of the size of the effects in our
outcome measures when using a parallel-group’s study
design. Magnitude-based inferences will also be calcu-
lated to examine the impact of exercise on all variables
of interest.
Power calculation and sample size
The sample size was calculated using statistical software
(G*Power 3.1.5) on the main outcome measure, fasting
serum insulin concentration. This calculation was based
on data from a hand-cycling training group, which re-
ported an improvement of −14.3 ± 12.7 pmol l−1 [59] in
fasting insulin over 16 weeks. Based upon these data
(Cohen’s d = −1.1) it was estimated that nine participants
are required to detect a statistically significant change in
insulin sensitivity in the INT group. The power was 0.8
and the alpha was set at 0.05. As a 2:1 ratio is to be
adopted, a computer programme (www.statstodo.com/
SSizUnequal_Pgm.php) was used to calculate sample size
adjustments for two groups with unequal size, to ac-
count for any consequences of unequal allocation on
statistical power [99]. Also, taking into account an ex-
pected drop-out rate of approximately 15 %, we aim to
recruit at least 24 (INT: 16, CON: 8) participants with
chronic paraplegia.
Discussion
To our knowledge, this will be the first study to simul-
taneously evaluate the efficacy of a home-based arm-
crank ergometry exercise intervention and explore the
biological mechanisms of action in persons with chronic
SCI. Considering the aforementioned barriers to engage
in PA, a convenient and accessible form of exercise is
necessary to maximise exercise compliance in this popu-
lation. A 16-week laboratory-based RCT [59], which ex-
perienced large drop-out rates, has recently advocated
that researchers should consider how to make exercise
interventions more feasible to individuals with SCI.
Home-based arm-crank ergometer exercise has been ex-
amined in other hard-to-reach groups (polio patients)
[100] and will overcome transportation barriers and the
lack of accessible exercise equipment. Changes in out-
come measures with increased PA, achieved through en-
hanced compliance, may indicate that home-based arm-
crank exercise has the potential to be used as a more
long-term behavioural strategy to improve clinical out-
comes and quality of life in persons with SCI.
Various exercise intervention protocols have been
employed for individuals with SCI previously, including
arm-crank ergometry [101], functional electrical stimula-
tion (FES) [102] or wheelchair propulsion [103] ranging
from between 5 to 57 weeks in duration. The frequency
of exercise in these studies was typically between two
and three sessions per week lasting 30 to 60 minutes per
session. We settled on the proposed intervention of
6 weeks of arm-crank exercise, 4 × 45 minutes per week,
in order to provide a considerable exercise stimulus.
Over this time-course we expect to see improvements in
our primary outcome measure of metabolic control, irre-
spective of weight loss (which may be negligible as a re-
sult of a compensatory increase in energy intake) [104].
Previous work has demonstrated that genes expressed
in skeletal muscle, related to both ‘insulin action’ and
‘adipocytokine signalling’ pathways, are downregulated
after 3 weeks of deconditioning in able-bodied males
and upregulated after 6 weeks of FES exercise training in
individuals with paralysis [105]. Building on these find-
ings, we speculate that 6 weeks of arm-crank exercise
will elicit favourable alterations in the expression of key
genes involved in energy homeostasis, glucose metabol-
ism, lipid metabolism and inflammatory pathways in
adipose tissue. By examining the expression of genes in-
volved in a variety of biological pathways, we hope to
further our understanding of the mechanisms whereby
PA might influence metabolic control and inflammation
in this population.
It is well established that high levels of habitual PA
and/or undertaking structured bouts of exercise can im-
prove aspects of immune function in healthy individuals
without a disability [48, 49, 106, 107]. However, it is un-
known whether these findings generalise to people with
SCI. Considering that: individuals with SCI exhibit less
robust immunity compared to regularly active, lean and
able-bodied people [50]; and that impaired immune
function has been reported in sedentary overweight indi-
viduals without a disability [45–47], then it is possible
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that disability-associated impairments in immune function
are brought about by sedentary behaviour and adipose tis-
sue accumulation/deregulation. This idea has never been
investigated. In the proposed work, we will examine the
magnitude of anti-viral cell-mediated immunity (i.e. T cell
IFN-γ production) in resting samples pre and post inter-
vention. This response is a functionally relevant and read-
ily observed measure of host immunity that can be
assessed sensitively with robust methodology.
The findings from this study might help to inform
new evidence-based PA guidelines specific to individuals
with a chronic SCI. By taking a holistic approach that
addresses a number of relevant outcome measures in a
single study, using a rigorous research design (RCT with
true control group), this study is in accordance with re-
cent recommendations [56, 108]. The results will also
act as a scientific platform for further interventional
studies in other diverse and at-risk populations.
Trial status
Enrolment into the study started on 1 September 2014.
As of 2 February 2016, 21/24 participants were recruited.
Recruitment is expected to be completed by 29 April 2016
and follow-up assessments in a further 8 weeks.
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